Literature DB >> 7822029

Differential expression of interferon regulatory factor 1 (IRF-1), IRF-2, and interferon consensus sequence binding protein genes in lipopolysaccharide (LPS)-responsive and LPS-hyporesponsive macrophages.

S A Barber1, M J Fultz, C A Salkowski, S N Vogel.   

Abstract

Macrophages secrete interferon (IFN), as well as other cytokines, following lipopolysaccharide (LPS) stimulation. The interferon regulatory factors (IRFs) comprise a family of DNA-binding proteins that have been implicated in the transcriptional regulation of IFN and certain IFN-inducible genes. We therefore characterized basal and LPS-inducible levels of IRF-1, IRF-2, and interferon consensus sequence binding protein (ICSBP) mRNA in LPS-responsive macrophages and compared the expression of these genes in macrophages that typify two murine models of LPS hyporesponsiveness. In the first model, the LPS-hyporesponsive phenotype of the C3H/HeJ mouse is genetically determined and maps to the Lps locus on mouse chromosome 4. In the second model, normally LPS-responsive macrophages acquire a transient LPS-hyporesponsive phenotype following a prior exposure to LPS, a phenomenon referred to as "endotoxin tolerance." Using reverse transcription PCR, we detected basal levels of IRF-1 mRNA in LPS-responsive (Lpsn) macrophages that were approximately 15 times higher than those found in LPS-hyporesponsive (Lpsd) macrophages. Conversely, Lpsd macrophages expressed basal levels of IRF-2 mRNA that were approximately 18 times higher than those expressed in Lpsn macrophages. LPS stimulation resulted in a dose- and time-dependent accumulation of IRF-1, IRF-2, and ICSBP mRNA only in Lpsn macrophages. Cycloheximide inhibited the accumulation of LPS-stimulated IRF-2 and ICSBP mRNA, but not IRF-1 mRNA, thus designating IRF-1 an immediate-early, LPS-inducible gene. Finally, macrophages rendered tolerant to endotoxin expressed elevated but nonmaximal mRNA levels for all three transcription factors that are not reinduced upon secondary challenge with LPS. Thus, the IRFs may represent yet an additional molecular pathway in the complex response to LPS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7822029      PMCID: PMC173039          DOI: 10.1128/iai.63.2.601-608.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

1.  Posttranscriptional regulation of interferon mRNA levels in peritoneal macrophages.

Authors:  S Gessani; P Di Marzio; P Rizza; F Belardelli; C Baglioni
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

2.  Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system.

Authors:  N Tanaka; T Kawakami; T Taniguchi
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

3.  Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development.

Authors:  T Matsuyama; T Kimura; M Kitagawa; K Pfeffer; T Kawakami; N Watanabe; T M Kündig; R Amakawa; K Kishihara; A Wakeham
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

4.  Activation of IFN-beta element by IRF-1 requires a posttranslational event in addition to IRF-1 synthesis.

Authors:  N Watanabe; J Sakakibara; A G Hovanessian; T Taniguchi; T Fujita
Journal:  Nucleic Acids Res       Date:  1991-08-25       Impact factor: 16.971

5.  Priming of human monocytes for enhanced lipopolysaccharide responses: expression of alpha interferon, interferon regulatory factors, and tumor necrosis factor.

Authors:  M P Hayes; K C Zoon
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

6.  Dissociation of lipopolysaccharide (LPS)-inducible gene expression in murine macrophages pretreated with smooth LPS versus monophosphoryl lipid A.

Authors:  B E Henricson; C L Manthey; P Y Perera; T A Hamilton; S N Vogel
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

7.  Induction of IFN-gamma in macrophages by lipopolysaccharide.

Authors:  M J Fultz; S A Barber; C W Dieffenbach; S N Vogel
Journal:  Int Immunol       Date:  1993-11       Impact factor: 4.823

8.  Requirement for transcription factor IRF-1 in NO synthase induction in macrophages.

Authors:  R Kamijo; H Harada; T Matsuyama; M Bosland; J Gerecitano; D Shapiro; J Le; S I Koh; T Kimura; S J Green
Journal:  Science       Date:  1994-03-18       Impact factor: 47.728

9.  Regulation of IFN-gamma-induced nuclear expression of IFN consensus sequence binding protein in murine peritoneal macrophages.

Authors:  A D Politis; K Ozato; J E Coligan; S N Vogel
Journal:  J Immunol       Date:  1994-03-01       Impact factor: 5.422

10.  Tyrosine phosphorylated p91 binds to a single element in the ISGF2/IRF-1 promoter to mediate induction by IFN alpha and IFN gamma, and is likely to autoregulate the p91 gene.

Authors:  R Pine; A Canova; C Schindler
Journal:  EMBO J       Date:  1994-01-01       Impact factor: 11.598

View more
  22 in total

1.  Use of differential display reverse transcription-PCR to reveal cellular changes during stimuli that result in herpes simplex virus type 1 reactivation from latency: upregulation of immediate-early cellular response genes TIS7, interferon, and interferon regulatory factor-1.

Authors:  R Tal-Singer; W Podrzucki; T M Lasner; A Skokotas; J J Leary; N W Fraser; S L Berger
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

Review 2.  Murine Models of Sepsis and Trauma: Can We Bridge the Gap?

Authors:  Julie A Stortz; Steven L Raymond; Juan C Mira; Lyle L Moldawer; Alicia M Mohr; Philip A Efron
Journal:  ILAR J       Date:  2017-07-01

3.  Interferon regulatory factor-2 is protective against hepatic ischemia-reperfusion injury.

Authors:  John R Klune; Rajeev Dhupar; Shoko Kimura; Shinya Ueki; Jon Cardinal; Atsunori Nakao; Gary Nace; John Evankovich; Noriko Murase; Allan Tsung; David A Geller
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-28       Impact factor: 4.052

4.  Epigenetic inhibition of lysyl oxidase transcription after transformation by ras oncogene.

Authors:  S Contente; K Kenyon; P Sriraman; S Subramanyan; R M Friedman
Journal:  Mol Cell Biochem       Date:  1999-04       Impact factor: 3.396

5.  IRF8 Regulates Transcription of Naips for NLRC4 Inflammasome Activation.

Authors:  Rajendra Karki; Ein Lee; David Place; Parimal Samir; Jayadev Mavuluri; Bhesh Raj Sharma; Arjun Balakrishnan; R K Subbarao Malireddi; Rechel Geiger; Qifan Zhu; Geoffrey Neale; Thirumala-Devi Kanneganti
Journal:  Cell       Date:  2018-03-22       Impact factor: 41.582

6.  Quantitative aspects of lipopolysaccharide and cytokine requirements to generate nitric oxide in macrophages from LPS-hyporesponsive (Lps(d)) C3H/HeJ mice.

Authors:  E Kmonícková; Z Zídek
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

7.  IRF-1 promotes liver transplant ischemia/reperfusion injury via hepatocyte IL-15/IL-15Rα production.

Authors:  Shinichiro Yokota; Osamu Yoshida; Lei Dou; Anthony V Spadaro; Kumiko Isse; Mark A Ross; Donna B Stolz; Shoko Kimura; Qiang Du; Anthony J Demetris; Angus W Thomson; David A Geller
Journal:  J Immunol       Date:  2015-05-11       Impact factor: 5.422

8.  Identification and characterization of interferon regulatory factor-1 from orange-spotted grouper (Epinephelus coioides).

Authors:  Yan Shi; Xin-Ping Zhu; Jing-Kui Yin; Qi-Ya Zhang; Jian-Fang Gui
Journal:  Mol Biol Rep       Date:  2009-05-15       Impact factor: 2.316

9.  In vivo footprinting of the mouse inducible nitric oxide synthase gene: inducible protein occupation of numerous sites including Oct and NF-IL6.

Authors:  C E Goldring; S Reveneau; M Algarté; J F Jeannin
Journal:  Nucleic Acids Res       Date:  1996-05-01       Impact factor: 16.971

10.  Induction of adrenomedullin mRNA and protein by lipopolysaccharide and paclitaxel (Taxol) in murine macrophages.

Authors:  M Zaks-Zilberman; C A Salkowski; T Elsasser; F Cuttitta; S N Vogel
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.